Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:+86-571-86130357
Add to Favorites
|
Online Feedback
中文
Home
|
About
|
Product
|
New Drug
|
Dream Works
|
Investor
|
Talent
|
Contact
Adhering to an innovative development philosophy to benefit the people, Betta Pharmaceuticals commits to the new drug development to achieve scientific innovation for the people, create more affordable medicines, and make people live better.
· Company Profile
· Directors
· Management Team
· Awards & Recognition
· Culture
· Icotinib
· Ensartinib
· Bevacizumab
·
·
· Tibremciclib
·
· OsrHSA
·
· R&D
· Pipeline
· Partner
· Park
·Core Strengths
· IR Contact
· Recruitment
· Campus
· Contact
News center
Company news
·
2020-02-05
·
2020-01-15
·
2020-01-10
·
2020-01-09
·
2019-12-25
·
2019-12-13
·
2019-12-12
· The phase III clinical trial of MIL60 has reached its primary endpoint
2019-12-05
·
2019-11-02
· Breaking news! Ensartinib clinical study results were published in The Lancet Respiratory Medicine
2019-10-16
Total514Record, every page10RecordCurrent number34/52Page
[
Home
]
[
Prev
]
[
32
]
[
33
]
[
34
]
[
35
]
[
Next
]
[
End
]
Copyright © 2019 All Rights Reserved Betta Pharmaceuticals Co., Ltd.
浙ICP备11052940号-2
Site Map
|
Copyright
|
Feedback
|
Enterprise E-Mail
|
OA Login